Low Molecular Weight Heparin in Atrial Fibrillation Management: Facts, Fiction, Future

ISSN： 1385-2264

Source： Cardiac Electrophysiology Review, Vol.7, Iss.4, 2003-12, pp. : 397-400

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit?

By Billett Henny Scorziello Barbara Giannattasio Emily Cohen Hillel

Journal of Thrombosis and Thrombolysis, Vol. 30, Iss. 4, 2010-11 ,pp. : 479-485

Springer Publishing Company

Access to resources Recommend Favorite

Low-molecular-weight Heparin During Pregnancy

By Bazzan M. Donvito V.

Thrombosis Research, Vol. 101, Iss. 1, 2001-01 ,pp. : 175-186

Elsevier

Access to resources Recommend Favorite

Low Molecular Weight Heparin and Neuraxial Anesthesia

By Horlocker T.T.

Thrombosis Research, Vol. 101, Iss. 1, 2001-01 ,pp. : 141-154

Elsevier

Access to resources Recommend Favorite

A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

By Mahan Charles

Journal of Thrombosis and Thrombolysis, Vol. 37, Iss. 3, 2014-04 ,pp. : 271-278

Springer Publishing Company

Access to resources Recommend Favorite

Advances in the Treatment of Atrial Fibrillation: The Future is Now: Current Topics in the Management of Atrial Fibrillation

By Naccarelli Gerald V.

Journal of Interventional Cardiac Electrophysiology, Vol. 10, Iss. 1, 2004-02 ,pp. : 77-78

Springer Publishing Company

Access to resources Recommend Favorite